CSL Behring Professor Heimburger Award Provides
100,000 Euros in Start-Up Grants to
Emerging Coagulation Investigators; Underscores CSL Behring's
Longstanding Commitment to Pioneering Science to Improve the Care
for Patients with Bleeding Disorders
MARBURG, Germany, April 23, 2015 /PRNewswire/ -- CSL
Behring announced today that the company has named five recipients
of the 2015 CSL Behring Professor Heimburger Award for
coagulation research. Now in its eighth year, the global awards
program helps fund the work of young, emerging researchers by
providing start-up grants. The goal of the award is to
encourage the next generation of coagulation specialists to
establish themselves professionally and to continue innovative
research. The total value of the five grants is 100,000 euros.
Recipients of the 2015 CSL Behring Professor Heimburger
Award were selected from more than 60 applicants, from 30
countries, by an independent committee of world-renowned
clinicians. This year's recipients, receiving 20,000 euros each, are:
- Ashwini Bennett, M.D.
Hematology Department, Level 4, Monash Health (Australia)
Neutrophil extracellular traps: Their role in acute venous
thromboembolism, sickle cell crisis and myeloproliferative
neoplasms
- Jenny Klintman, M.D.
Skane University Hospital, Clinical Collaboration Research Unit
Lund University (Sweden)
Clinical evaluation and characterization of suspected atypical
hemolytic uremic syndrome (aHUS)
- Tesse Leunissen, M.D.
University Medical Centre Utrecht (Netherlands)
High accuracy platelet function testing to predict perioperative
micro embolic signals (MES) during carotid endarterectomy
(CEA)
- Michelle Sonneveld, M.D.
Erasmus University Medical Center
(Netherlands)
Complement factor H and the relation with von Willebrand Factor and
ADAMTS13
- Bryce Andrew Kerlin, M.D.
Associate Professor of Pediatrics, The Ohio
State University College of Medicine (U.S.)
Thrombin signaling mechanisms in nephrotic syndrome
"Coagulation disorders can be debilitating for patients and have
a negative impact on their quality of life," said Jens Oltrogge, Ph.D., Senior Director,
Commercial Development Coagulation, CSL Behring. "Professor
Heimburger was a pioneer in improving the care for patients with
coagulation disorders. Supporting these young investigators
dedicated to advancing coagulation therapy, in his honor,
underscores CSL Behring's longstanding commitment to improving
patient outcomes through science and innovation. We would like to
congratulate all of the recipients of the 2015 CSL Behring
Professor Heimburger Award and wish them success with their
research."
More information about the CSL Behring Professor Heimburger
Award, including the names of previous winners, can be found
at:
http://www.cslbehring.com/products/bleeding-disorders/professor-heimburger-award.htm
About Professor Heimburger
Professor Norbert Heimburger was an employee of CSL
Behring for more than 30 years and devoted his work to blood
coagulation. One of his major contributions in this area was the
development of virus-safe plasma products based on pasteurization;
a development that led CSL Behring to produce the world's first
virus-inactivated factor VIII concentrate to treat hemophilia
patients.
About CSL Behring's Commitment to Advancing Coagulation
Science
CSL Behring has a commitment to innovation and a
thorough understanding of the bleeding disorders community.
Through this commitment and understanding, CSL Behring continues to
advance its recombinant factor development program.
The AFFINITY clinical development program is studying CSL
Behring's recombinant Factor VIII SingleChain (rVIII-SingleChain)
to treat hemophilia A and the PROLONG-9FP clinical trial program is
studying the company's recombinant fusion protein linking
coagulation factor IX with recombinant albumin (rIX-FP) to treat
hemophilia B. Regulatory submissions for rIX-FP are currently being
reviewed by the U.S. Food and Drug Administration and European
Medicines Agency. CSL Behring also continues to advance its
long-acting recombinant fusion protein linking recombinant
coagulation factor VIIa with recombinant albumin (rVIIa-FP) to
control bleeding episodes in hemophilia patients who have
inhibitors.
Pivotal data from CSL Behring's recombinant factor development
program will be presented during the International Society on
Thrombosis and Haemostasis (ISTH) Congress in Toronto in June
2015.
About CSL Behring
CSL Behring is a leader in the
plasma protein therapeutics industry. Committed to saving lives and
improving the quality of life for people with rare and serious
diseases, the company manufactures and markets a range of
plasma-derived and recombinant therapies worldwide.
CSL Behring therapies are used around the world to treat
coagulation disorders including hemophilia and von Willebrand
disease, primary immune deficiencies, hereditary angioedema and
inherited respiratory disease, and neurological disorders in
certain markets. The company's products are also used in cardiac
surgery, organ transplantation, burn treatment and to prevent
hemolytic disease of the newborn.
CSL Behring operates one of the world's largest plasma
collection networks, CSL Plasma. CSL Behring is a global
biopharmaceutical company and a member of the CSL Group of
companies. The parent company, CSL Limited (ASX:CSL), is
headquartered in Melbourne,
Australia. For more information, visit
www.cslbehring.com.
Contacts:
Jack
Herberg
CSL Behring
Office: + 49 (0) 6421 39 4022
Hans.Herberg@CSLBehring.com
Greg Healy
CSL Behring
Office: 610-878-4841
Mobile: 610-906-4564
Greg.Healy@CSLBehring.com
Logo -
http://photos.prnewswire.com/prnh/20100914/PH63692LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/csl-behring-awards-young-researchers-around-the-world-to-advance-coagulation-science-300071014.html
SOURCE CSL Behring